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Abstract
Background: To profile the expression of microRNAs (miRNAs) and their potential target genes in the gracilis muscles 
following ischemic injury in rats by monitoring miRNA and mRNA expression on a genome-wide basis.
Methods: Following 4 h of ischemia and subsequent reperfusion for 4 h of the gracilis muscles, the specimens were 
analyzed with an Agilent rat miRNA array to detect the expressed miRNAs in the experimental muscles compared to 
those from the sham-operated controls. Their expressions were subsequently quantified by real-time reverse 
transcription polymerase chain reaction (real-time RT-PCR) to determine their expression pattern after different 
durations of ischemia and reperfusion. In addition, the expression of the mRNA in the muscle specimens after 4 h of 
ischemia and reperfusion for 1, 3, 7, and 14 d were detected with the Agilent Whole Rat Genome 4 × 44 k oligo 
microarray. A combined approach using a computational prediction algorithm that included miRanda, PicTar, 
TargetScanS, MirTarget2, RNAhybrid, and the whole genome microarray experiment was performed by monitoring the 
mRNA:miRNA association to identify potential target genes.
Results: Three miRNAs (miR-21, miR-200c, and miR-205) of 350 tested rat miRNAs were found to have an increased 
expression in the miRNA array. Real-time RT-PCR demonstrated that, with 2-fold increase after 4 h of ischemia, a 
maximum 24-fold increase at 7 d, and a 7.5-fold increase at 14 d after reperfusion, only the miR-21, but not the miR-
200c or miR-205 was upregulated throughout the experimental time. In monitoring the target genes of miR-21 in the 
expression array at 1, 3, 7, 14 d after reperfusion, with persistent expression throughout the experiment, we detected 
the same 4 persistently downregulated target genes (Nqo1, Pdpn, CXCL3, and Rad23b) with the prediction algorithms 
miRanda and RNAhybrid, but no target gene was revealed with PicTar, TargetScanS, and MirTarget2.
Conclusions: This study revealed 3 upregulated miRNAs in the gracilis muscle following ischemic injury and identified 
4 potential target genes of miR-21 by examining miRNAs and mRNAs expression patterns in a time-course fashion 
using a combined approach with prediction algorithms and a whole genome expression array experiment.
Background
Skeletal muscle ischemia is an important clinical problem
that may result in a significant high rate of morbidity and
mortality. Despite extensive experimental work that is
directed toward the treatment and prevention of estab-
lished ischemic injuries, the clinical outcome has not
appreciably changed over the past decades [1]. This may
be related to the fact that the pathophysiology of this
complex event is still incompletely understood. The
microRNAs (miRNAs) are a novel regulatory class of
noncoding, single-stranded RNAs of approximately 22
nucleotides, which have recently been identified to play
critical roles in normal development and physiology, as
well as in disease development [2,3]. The discovery of
miRNAs has broadened the overall understanding of the
mechanisms that regulate gene expression, with the addi-
tion of an entirely novel level of regulatory control. Both
basic and clinical studies suggest that miRNAs are impor-
tant regulators of cell differentiation, growth, prolifera-
tion, and apoptosis [4-6]. Estimates indicate that miRNAs
may regulate up to one-third of the mammalian genome
[7]. However, each miRNA possibly targets many differ-
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ent mRNAs and the same target gene may be regulated by
a given miRNA in different situations, allowing for enor-
mous complexity and flexibility in their regulatory poten-
tial [7-9]. Therefore, although a large number of miRNAs
have been discovered, only a few target genes have been
identified and the functions of most of them remain
unknown.
The miRNAs repress protein expression at the post-
transcriptional level, mostly through base pairing to the 3'
untranslated region (UTR) of the target mRNA, thus
leading to its degradation and/or reduced translation.
Earlier, miRNAs were thought to primarily repress their
target genes at the protein level without affecting mRNA
stability [10,11]; however, increasing evidence indicates
that miRNAs silence genes by multiple mechanisms,
including the degradation of their target mRNAs [12,13].
For the more highly repressed targets, mRNA destabiliza-
tion usually constituted the major component of repres-
sion [14], thus making the investigation of the
mRNA:miRNA association by monitoring miRNA and
mRNA expression on a genome-wide basis a novel ana-
lytical approach to understand the miRNA-mediated reg-
ulation [15,16].
Dysregulated miRNA expression has been reported to
be involved in the transient focal ischemic brain [16,17]
and in the ischemia-reperfusion injury of the heart
[18,19]. In addition, the endogenously synthesized miR-
NAs demonstrated to be cardioprotective following isch-
emia-reperfusion injury [19]. Moreover, there is
increasing evidence for the involvement of microRNA in
myopathies [20-22]; a number of microRNAs have been
characterized as regulators of skeletal muscle develop-
ment and diseases [23,24] as well as of skeletal muscle
remodeling [25]. Given the importance of miRNAs in the
pathophysiology of the muscle, we hypothesized that
microRNAs could be involved in the skeletal muscle in
response to ischemic injury. First, we addressed this
hypothesis using a microarray-based screening. The
expression profile was subsequently verified with real-
time reverse transcription polymerase chain reaction
(real-time RT-PCR). Potential target genes were identi-
fied by monitoring the miRNA and mRNA expression on
a genome-wide basis.
Methods
Animal surgery and tissue preparation
The experiments were performed on adult male Sprague-
Dawley rats weighing 250-300 g. The rats were randomly
assigned to the sham-operated control group and the
ischemic group. The rats were anesthetized by an intrap-
eritoneal injection of 500 mg/kg chloral hydrate and pre-
pared in the prone position. The gracilis muscle flap was
dissected under the microscope by the same surgeon. The
flap was isolated on its dominant and minor vascular
pedicles. We used a standard microvascular technique for
the sham-operated control group. The minor vascular
pedicle was electrocauterized and transected. Ischemia
was induced in the ischemic group by placing a microvas-
cular clamp carefully across the proximal dominant vas-
cular pedicle to the gracilis muscle. The gracilis muscle
was allowed to perfuse in the sham-operated control
group. After the indicated ischemic time (0.5, 1, 2, and 4
h), the microvascular clamp was removed. Good vascular
inflow and outflow through the pedicle was verified
under direct magnified vision. The incision wound was
closed with interrupted sutures (4-0 nylon) and the ani-
mals were allowed to awaken in the remaining periods of
reperfusion. For the miRNA array experiments, gracilis
muscles after 4 h of ischemia and 4 h of reperfusion were
used in 2 replicate experiments. First, we performed eval-
uation experiments to determine the minimal ischemic
time that would induce miRNA expression before we
investigated the miRNA expression in the real-time RT-
PCR experiments. For that, the muscle specimens were
either harvested after 4 h of ischemia and reperfusion for
0, 2, 4, 8, and 24 h and for 3, 7, and 14 d or the ischemia
times were set at 0.5, 1, and 2 h with perfusion for 4 h. We
used the muscle specimens that underwent ischemic
injury at 1, 3, 7, and 14 d after reperfusion for the whole
genome expression experiments. The harvested muscles
were frozen in isopentane chilled in liquid nitrogen and
stored at -80°C. All housing, surgical procedures, analge-
sia, and assessments were performed in accordance with
the Animal Care Guidelines and were approved by the
Animal Care Committee at the Chang Gung Memorial
Hospital.
RNA isolation
Total RNA was extracted using the mirVana miRNA Iso-
lation kit (Ambion, Austin, TX, USA). The purified RNA
was quantified by determining the absorbance at 260 nm
using an SSP-3000 Nanodrop spectrophotometer (Infini-
gen Biotech, City of Industry, CA, USA). The quality of
the purified RNA was evaluated on a Bioanalyzer 2100
(Agilent Technologies, Palo Alto, CA, USA) for the
miRNA array and whole genome expression analyses.
Expression of miRNAs
A rat miRNA array (G4473A, Agilent Technology) which
includes 350 rat miRNAs (Sanger miRBase Release 10.1)
was used to identify the upregulated miRNAs in the gra-
cilis muscles after 4 h of ischemia and 4 h of reperfusion,
with total four one-color miRNA arrays for two sham-
operated and two experimental muscle specimens. One
hundred nanogram of total RNA was dephosphorylated
for 30 min at 37°C with 11.2 units calf intestine alkaline
phosphatase (GE Healthcare Life Sciences, Uppsala, Swe-
den). The reaction was terminated by heating at 100°C forHsieh et al. BMC Musculoskeletal Disorders 2010, 11:123
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5 min and immediate cooling to 0°C. DMSO (5 μl) was
then added. The solution was heated to 100°C for 5 min
and immediately cooled to 0°C. Ligase buffer and BSA
were added and ligation was performed by adding pCp-
Cy3 (50 μM) and 15 units T4 RNA ligase in 28 μl. The
mixture was incubated at 16°C for 2 h. The labeled miR-
NAs were desalted with MicroBioSpin6 columns (Bio-
Rad, Hercules, CA, USA). Subsequently, 2× hybridization
buffer was added to the labeled mixture to a final volume
of 45 μl. The mixture was heated for 5 min at 100°C and
immediately cooled to 0°C. Each 45-μl sample was
hybridized onto an miRNA array at 55°C for 20 h. After
hybridization, the slides were washed at room tempera-
ture for 5 min in Gene Expression W ash Buffer 1 and
then for 5 min in Gene Expression W ash Buffer 2. The
slides were scanned on an Agilent microarray scanner
G2565A. The sensitivity settings were 100% and 5%. Agi-
lent Feature Extraction software version 9.5.3 was used
for image analysis. The microarray data were analyzed
using GeneSpring GX 7.3.1 (Agilent Technologies). The
miRNA expression was considered significantly different
when values in the muscles of the experimental rats were
more than double of those of the sham-operated controls
in 2 replicate experiments. ANOVA was employed to
compare the average values of the miRNA probes in all
samples and yielded significant P  values (<0.05) in all
cases.
Quantification of miRNAs expression
Those upregulated miRNAs (miR-21, miR-200c, and
miR-205) that were identified from the miRNA array
were quantified by real-time RT-PCR with the Applied
Biosystems 7500 (Applied Biosystems, USA). We isolated
total RNA from the harvested muscle with the mirVana
miRNA Isolation Kit (Ambion, USA) as well as a TaqMan
miRNA Assay kit (Applied Biosystems, USA) according
to the manufacturers' instructions. The thermal cycling
conditions comprised an initial denaturation step at 95°C
for 10 min and 40 cycles at 95°C for 15 s and 60°C for 1
min. Each value of miRNA expression was represented
relative to the expression of small RNA 4.5 S, which was
used as an internal control. The fold-expression of induc-
t i o n  w a s  c a l c u l a t e d  a s  t h e  r e l a t i v e  e x p r e s s i o n  v a l u e s
obtained in each condition in conjunction with the stan-
dard deviation compared with the relative expression val-
ues from the gracilis muscles of the sham-operated
control group. The comparison between the groups
included ANOVA and the appropriate posthoc test to
compensate for multiple comparisons (SigmaStat, San
Rafael, CA, USA). P-values of less than 0.05 were consid-
ered significant.
Whole Genome Microarray Analyses
Four two-color Whole Rat Genome 4 × 44 k oligo
microarrays (Agilent Technologies) were used to detect
the change of the transcripts in the experimental gracilis
muscles. Expression levels of the mRNAs in the gracilis
muscles after 4 h of ischemia and 1, 3, 7, and 14 d of rep-
erfusion with 1 specimen at each of the abovementioned
time points were detected with the oligo microarray and
compared against those expression levels of the sham-
operated control specimens at the same indicated time.
The microarray experiments were carried out according
to the manufacturer's protocols. In brief, 0.5 μg of total
RNA was amplified using a Fluorescent Linear Amplifica-
tion Kit (Agilent Technologies) and labeled with Cy3-
CTP or Cy5-CTP (CyDye, PerkinElmer, CA, USA) during
the  in vitro transcription process. The RNA from the
experimental muscle was labeled with Cy5 and the RNA
from the sham-operated control muscle RNA was labeled
with Cy3. Then, 0.825 μg of the Cy-labeled cRNA was
fragmented to an average size of about 50-100 nucle-
otides by incubation with the fragmentation buffer (Agi-
lent Technologies) at 60°C for 30 min. Subsequently, the
fragmented labeled cRNA was pooled and hybridized to
the Whole Rat Genome microarray at 60°C for 17 h. After
washing and drying with a nitrogen gun, the microarrays
were scanned with an Agilent microarray scanner (Agi-
lent Technologies) at 535 nm for Cy3 and 625 nm for Cy5.
The scanned images were analyzed with the Feature
Extraction software 9.5.3 (Agilent Technologies). We
used image analysis and normalization software to quan-
tify the signal and background intensity for each feature
and to substantially normalize the data by the rank-con-
sistency-filtering LOWESS method. The differentially
expressed mRNAs were selected if there was a 2-fold
change between the experimental muscles and the sham-
operated control muscles.
Prediction of the potential target genes of miRNAs
To date, there is not 1 algorithm that outperforms others
in terms of sensitivity and specificity. We identified the
potential targets of those upregulated miRNAs by com-
bined analysis of the downregulated mRNAs in the whole
genome expression microarray and the commonly used
web tools for bioinformatics algorithms, including 3 of
the most used prediction websites: miRanda http://
www.microrna.org/microrna/home.do, PicTar http://pic-
tar.mdc-berlin.de/, and TargetScanS http://www.tar-
getscan.org/, as well as 2 additional algorithms,
MirTarget2 http://mirdb.org/miRDB/ and RNAhybrid
http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/. The
in silico predicted targets genes were compared to the list
of 2-fold downregulated mRNA transcripts (derived from
the whole rat genome microarray experiments) by exam-Hsieh et al. BMC Musculoskeletal Disorders 2010, 11:123
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ining miRNAs:mRNAs expression pairs in a time-course
fashion. The genes that were identified in both methods
were considered as potential target genes regulated by a
given miRNA.
Results
Expression profile of the miRNAs
In the investigation of the differentially expressed miR-
NAs from the miRNA array experiments, there were only
3 miRNAs (miR-21, miR-200c, and miR-205) that showed
an increased expression in the gracilis muscles after 4 h of
ischemia and 4 h of reperfusion. We confirmed the
microarray data by quantitative real-time RT-PCR to
independently measure the relative expression of these 3
selected miRNAs in the samples of the experimental
muscle. As shown in Figure 1, the 2-fold upregulation of
miR-21 was detected after 4 h of ischemia and increased
to a maximum of ~24 fold at 7 d after reperfusion. At 14
d, there was still a 7.5-fold increased expression of miR-
21. The miR-200c expression was increased 3.2 fold and
was detected 2 h after reperfusion following 4 h of isch-
emia. The expression of miR-200c reached its maximum
level at 4 h and lasted for up to 8 h after ischemic injury.
We did not detect an increased expression of miR-200c 1
d after reperfusion. A 6.4-fold upregulation of miR-205
was detected after 4 h of ischemia. It gradually decreased
to 3.6-fold at 4 h after reperfusion. No significant differ-
ence in the expression of miR-205 was found at 8 h, 1 d,
and 3 d after ischemic injury. Unexpectedly, we noted the
3.6-fold upregulation of miR-205 7 d later. This status
persisted until 14 d after ischemic injury. In the experi-
ment that we performed to identify the minimal ischemic
time that would induce the expression of these 3 miR-
NAs, upregulation of miR-21 and miR-200c was noted
after 4 h of reperfusion following 1 h and 2 h, but not 30
min of ischemia; in addition, upregulation of miR-205
was noted after 4 h of reperfusion following 2 h, but not
30 min or 1 h of ischemia (Figure 2).
Finding the potential miRNA-regulated genes
Time-course studies provide information for the identifi-
cation of miRNA-target mRNA pairs that could often be
missed in a cross-sectional study when a single time point
is used [26]. Thus, we examined mRNA expression pat-
terns at the 4 indicated times (1, 3, 7, and 14 d after isch-
emic injury) based on the matched analysis of miRNA
and mRNA expression data and considered an miRNA to
be regulatory only if the upregulation in the expression
profile of the miRNA and its predicted target mRNAs
correlated. The miR-200c and miR-205 were not upregu-
lated at all 4 indicated times. In addition, there was still
lack of evidence regarding the effect on the persistent
knockdown of mRNAs by an elevated miRNA. Therefore,
we decided to only focus on the genes that were downreg-
ulated by miR-21, which showed a persistent expression
throughout the experiment period at all 4 indicated
times. The expression profiling using the Agilent rat 60-
mer oligonucleotide microarrays showed there was a
global pattern of differentially expressed genes at 1, 3, 7,
and 14 d after ischemic injury. Expression profiling
revealed that there were 1046 significantly downregu-
lated gene transcripts in the experimental muscles (abso-
lute expression changes were 2-fold or greater) at all 4
indicated times. In addition, the in silico prediction using
the algorithms miRanda, PicTar, TargetScanS,
MirTarget2, and RNAhybrid resulted in 957, 60, 159, 110,
and 939 target genes of miR-21, respectively. The combi-
nation of the results of the computational prediction of
Figure 1 Expression of miR-21, miR-200c, and miR-205 detected with real-time RT-PCR in the gracilis muscles following 4 h of ischemia and 
reperfusion for indicated times. Bars represent means ± standard deviation of 6 independent experiments; *, P < 0.05 vs. sham-operated control.Hsieh et al. BMC Musculoskeletal Disorders 2010, 11:123
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target genes of miR-21 and the downregulation of genes
in the whole genome expression array at 4 indicated times
revealed no target gene on the basis of the prediction
algorithms PicTar, TargetScanS, and MirTarget2; in con-
trast, when the prediction algorithms miRanda and
RNAhybrid were applied, the same 4 target genes (Nqo1,
Pdpn,  CXCL3, and Rad23b)  ( T a b l e  1 )  d e m o n s t r a t e d  a
persistent downregulated status at 1, 3, 7, and 14 d (Fig-
ure 3). The miRNA array and the microarray data have
been deposited in the Gene Expression Omnibus (acces-
sion number [GEO: GSE21423]).
Discussion
In this study, we demonstrated that 3 miRNAs (miR-21,
miR-200c, and miR-205) were significantly upregulated in
a different pattern in the gracilis muscles following isch-
emic injury. Ischemia for only 1 h was sufficient to induce
the expression of miR-21 and miR-200c during the reper-
fusion stage; and 2 h of ischemia were required to induce
the expression of miR-205. Our data also showed that
miR-200c and miR-205 were actively regulated after isch-
emia but their expression pattern changed after reperfu-
sion, indicating their temporal expression during
ischemic injury. In addition, with a yet to be determined
mechanism, we noted a significant re-expression of miR-
205 at 7 and 14 d after the injury. In contrast, the expres-
sion of miR-21 gradually increased to its maximum level
at 7 d and persisted throughout the experiment for at
least 14 d after the ischemic injury. This finding might
imply an important role of miR-21 during ischemic injury
in the muscle.
The overexpression of miR-21 has been shown to be in
a number of medium-scale and high-scale profiling
experiments that were designed for the detection of miR-
NAs that are dysregulated in cancer [27]. In addition,
miR-21 has been reported to have anti-apoptotic proper-
ties in cancer cells [28,29]. It has been reported that miR-
21 protects against the hydrogen peroxide-induced injury
Table 1: The potential regulated gene targets of rno-miR-21
Symbol Full Name Transcript ID Gene Type
Nqo1 NAD(P)H dehydrogenase, quinone 1 ENSRNOT00000017174 Protein coding
Pdpn podoplanin ENSRNOT00000020316 Protein coding
Cxcl3 chemokine (C-X-C motif) ligand 3 ENSRNOT00000033592 Protein coding
Rad23b RAD23 homolog B ENSRNOT00000021629 Protein coding
Potential target genes of rno-miR-21 that were identified from downregulated mRNA in the experimental muscles in the whole genome 
expression array experiments after reperfusion for 1, 3, 7, and 14 d following 4 h of ischemia as well as from either the miRanda or RNAhybrid 
prediction algorithm.
Figure 2 Expression of miR-21, miR-200c, and miR-205 detected with real-time RT-PCR in the gracilis muscles following indicated ischemic 
times (30 min, 1 h, and 2 h) and reperfusion for 4 h. Bars represent means ± standard deviation of 5 independent experiments; *, P < 0.05 vs. sham-
operated control.Hsieh et al. BMC Musculoskeletal Disorders 2010, 11:123
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of cardiac myocytes via its target gene, the repressor gene
programmed cell death 4 (PDCD4), and the AP-1 path-
way [30]. The hydrogen peroxide-induced cardiac cell
death and apoptosis were increased by a miR-21 inhibitor
and was decreased by pre-miR-21 transfection [30]. In
addition, a significant induction of miR-21 was noted in
the heart following whole body heat-shock [19]. The
injection of chemically synthesized exogenous miR-21
significantly reduced infarct size in the heart which was
blocked with a miR-21 inhibitor [19]. In an investigation
of rat hearts at 6 h after acute myocardial injury, miRNA
signatures in the early phase revealed that, among multi-
ple aberrantly expressed miRNAs, miR-21 was signifi-
cantly downregulated in infarcted areas, but was
upregulated in border areas [31]. Remarkably, the down-
regulation of miR-21 in infarcted areas was inhibited by
ischemic preconditioning, a known cardio-protective
method. In addition, adenoviral overexpression of miR-
2 1  h a d  a  p r o t ect i v e  e f f ect  o n  m y oca r d ia l  i n fa r ct i o n  b y
decreasing the infarct size by 29% at 24 h [31]. In this
study, we found 4 potential target genes (Nqo1,  Pdpn,
CXCL3, and Rad23b) of miR-21 during skeletal muscle
ischemic injury. The database of experimentally validated
miRNA target genes, MiRecords [32], lists 26 validated
target genes of miR-21 in humans (TPM1, CDK6, TIMP3,
PDCD4,  SERPINB5,  NFIB,  CDKN1A,  FAS,  FAM3C,
HIPK3,  PRRG4,  ACTA2,  BTG2,  BMPR2,  SESN1,  IL6R,
SOCS5, GLCCI1, APAF1, SLC16A10, SGK3, RP2, CFL2,
RECK, MTAP, SOX5) and only 2 validated target genes in
the rat (ITGB1, Tagln). Interestingly, the 4 genes that we
identified in this study did not match with the already val-
idated target genes in humans or rats. Among these 4
identified target genes, podoplanin (Pdpn) is a transmem-
brane glycoprotein and is expressed in many normal
human tissues including the skeletal muscle [33]. Pdpn is
widely used as a specific marker for lymphatic endothelial
cells and lymphangiogenesis in many species because it is
expressed on lymphatic but not on blood vessel endothe-
lium [33]. Deficiency of Pdpn results in congenital lym-
phedema and impaired lymphatic vascular patterning
[34]. With the postfix L (for ligand) or postfix R (for
receptor), CXCL and CXCR are used as ligands and
receptors of the CXC chemokine family which exhibits
both angiogenic and angiostatic properties [35]. While
chemokines can exert a pro-angiogenic effect via recruit-
ment of inflammatory cells, CXCL3  is induced in the
human perihematomal tissue [36] and can mediate angio-
genesis in the absence of preceding inflammation [35].
The nucleotide excision repair (NER) protein, Rad23b,
was found to be downregulated in hypoxic cancer cells
[37]. Hypoxia can also promote genetic instability by
affecting the DNA repair capacity, including NER which
primarily focuses on helix-distorting injuries [38]. The
downregulation of Rad23b in hypoxic cancer cells could
be partially reversed by antisense inhibition of miR-373
[37], indicating a key role of miR-373 in modulating the
basal expression of Rad23b. The effect of anti-miR-373
activity in normoxia is more profound than in hypoxia;
thus, it has been suggested that there might be other
mechanisms that regulate the expression of Rad23b [37].
In reviewing the literature, no direct linkage between
these 4 identified target genes and the muscle ischemic
injury was found. Only the detoxification enzyme
NAD(P)H: quinone oxidoreductase 1 (Nqo1) could be
correlated to the ischemic injury in renal tissue [39] and
primary cultures of rat cortex [40], but with different out-
comes regarding the cytoprotective effect. As a detoxifi-
cation enzyme Nqo1 catalyzes the 2-electron reduction
of quinoid compounds to the readily excreted hydroqui-
nones, thereby preventing the generation of reactive oxy-
gen species and protecting cells against oxidative damage
[41]. The expression of the Nqo1 gene is primarily regu-
lated via antioxidant response element sequences in the
promoter region. Reoxygenation-specific activation of
the antioxidant transcription factor Nrf2 mediates the
cytoprotective gene expression during ischemia-reperfu-
sion injury [42]. However, some authors suggested a dete-
riorating rather than a protective factor of Nqo1 in the
progression of neuronal cell death, as inhibition of Nqo1
by various inhibitors protects against neuronal damage in
vitro and following cerebral ischaemia in vivo [40].
Because bioinformatic analysis has indicated that miR-
NAs frequently interact with transcription factors in
feedback and feedforward loops to regulate their target
genes [43,44]; therefore, further experiments are required
to elucidate the function and role of these potential target
Figure 3 The expression of down-regulated Nqo1, Pdpn, CXCL3, 
and Rad23b, which were the potential target genes of rno-miR-21 
detected from the combined approach of the prediction algo-
rithms miRanda and RNAhybrid, in the Whole Rat Genome 4 × 44 
k oligo microarray experiments of the gracilis muscle after reper-
fusion for 1, 3, 7, and 14 d following 4 h of ischemia.Hsieh et al. BMC Musculoskeletal Disorders 2010, 11:123
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genes and the upregulated miR-21, as well as miR-200c
and miR-205, in ischemic injury.
The pneumatic tourniquet is frequently used in surgery
to acquire a bloodless operative field. To prevent the isch-
emia-reperfusion injury, the maximal allowable ischemic
time of the pneumatic tourniquet is 2 h [45,46] Although
minor histological changes in muscle started to appear
after about 35-40 minutes, there was no clinical evidence
of irreversible muscle damage within 2 h [45-47]; this is
also the reason why most of the article studying the isch-
emic injury of skeletal muscle would choose the ischemic
time at 4 h or a longer ischemic time. Whether there is a
different miRNAs expression profile after a shorter time
of ischemia such as 1 h or 2 h is unknown, but if these
miRNAs are not up-regulated in a longer hour ischemia,
the investigation of these targets may be devoid of clinical
importance or attention. Therefore, in this study, we were
not intended to profile the miRNAs expression with a
miRNA array at a shorter time, like 2 h, of ischemia.
However, as shown in the Figure 2, in the investigation of
minimal ischemic time that would induce the expression
of these 3 miRNAs, we had demonstrated that 1 h of isch-
emia was able to increase the expression of miR-21 and
miR-200c and 2 h of ischemia would increase the expres-
sion of these three miRNAs, implying the epigenetic reg-
ulation could be induced by a shorter time of ischemia
before a remarked pathophysiologic change could be
observed by a longer time of ischemia.
Bioinformatic algorithms remain the principal means
of predicting targets of specific miRNAs. These algo-
rithms take into account numerous parameters that influ-
ence miRNA/target interactions, including seed match
(complementarity), 3'-UTR seed match context, seed
match conservation, favorability of free energy binding,
AU content, and binding site accessibility [48]. To identify
miRNAs that regulate mRNAs, one needs to co-analyze
the changes in miRNA and mRNA expressions. The
investigation of the mRNA:miRNA association monitors
the miRNA and mRNA expression on a genome-wide
basis and provides an analytical approach to reveal the
target genes of the miRNA [49,50]. However, some limi-
tations still remain for the combined approach method
that we described here. First, it might be overly simplistic
to correlate miRNAs and their predicted targets primarily
on the basis of the number of consensus sites in the
3'UTR because an exact match to the sequence of the
seed region is not required. For example, miRanda typi-
cally produces more potential targets than other pro-
grams, but a large number of false targets would seriously
limit the value of the output information [51]. In contrast,
some available programs with stricter criteria, e.g., the
prediction algorithms PicTar, TargetScanS, and
MirTarget2 have only partially overlapping predicted tar-
gets for the same miRNA and produce smaller data sets
than miRanda [52]. In this present study, in order to
reduce the noise from the calculation of the correlation
between miRNA and mRNAs (based on the time-course
expression values), the inclusion of downregulated genes
at all 4 time points might have been too strict to acquire
potential target genes. In addition, it might have pro-
duced a smaller number of predicted targets after corre-
lation with the stricter prediction algorithm considering
the accuracy and reproducibility of the whole genome
array. For example, no target genes were found for the
combination with the prediction algorithms PicTar, Tar-
getScanS, and MirTarget2. Due to the differences among
databases and because there is no clear superior method,
a further gain-of-function or loss-of function experiment
would be helpful to elucidate the role of the identified tar-
get genes and that of each associated miRNA. Further-
more, it has been reported that more than a third of those
translationally repressed target genes always displayed
detectable mRNA destabilization [14]. However, the
extent of miRNA function in animal cells has largely been
studied by mRNA microarray profiling assuming that
miRNA function leads to reduced mRNA levels, which
may not be always the case. There might be some uniden-
tified target genes that are repressed only in the transla-
tion process but have not been subjected to mRNA
degradation.
Conclusions
This study has profiled an increased expression of miR-
21, miR-200c, and miR-205 in the gracilis muscle follow-
ing ischemic injury and identified four potential target
genes (Nqo1, Pdpn, CXCL3, and Rad23b) of the miR-21
by using different prediction algorithms and monitoring
the expression of miRNA and mRNA at different time
point on a genome-wide basis. Although the exact roles
of these upregulated miRNAs following ischemic injury
remains to be elucidated, this study provides a novel
insight into the epigenetic regulation in the skeletal mus-
cle following ischemic injury.
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